We acted as special product counsel to the representatives of the several underwriters on the offering

Davis Polk acted as special product counsel to the representatives of the several underwriters in connection with an SEC-registered offering by Viridian Therapeutics, Inc. of an aggregate principal amount of $250 million of its 1.75% convertible senior notes due 2032, which included the full exercise of the underwriters’ over-allotment option.

Viridian is a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for patients with autoimmune and rare diseases.

The Davis Polk equity derivatives team included partner Randall Derek Walters, counsel M. Faisal Baloch and associate Melissa X. Estrada. The tax team included partner Aliza Slansky, counsel Dustin Plotnick and associate Georgianna Eck. All members of the Davis Polk team are based in the New York office.

Copy link to share post